Knoll Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Knoll Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-210,789	Closed	-$2.6M	–	43
2022 Q1	$2.6M	Buy	+210,789	New	+$2.59M	1.63%	7
2021 Q1	–	Sell	-670,789	Closed	-$3.62M	–	40
2020 Q4	$3.62M	Buy	670,789 +50,000	+8%	+$263K	2.47%	8
2020 Q3	$2.83M	Sell	620,789 -103,416	-14%	-$445K	2.32%	8
2020 Q2	$3.62M	Hold	724,205	–	–	2.09%	7
2020 Q1	$2.28M	Hold	724,205	–	–	2.14%	8
2019 Q4	$1.88M	Hold	724,205	–	–	1.39%	12
2019 Q3	$2.29M	Hold	724,205	–	–	2.09%	12
2019 Q2	$2.44M	Hold	724,205	–	–	2%	11
2019 Q1	$2.21M	Hold	724,205	–	–	1.68%	11
2018 Q4	$1.13M	Hold	724,205	–	–	1.29%	9
2018 Q3	$1.87M	Hold	724,205	–	–	1.58%	9
2018 Q2	$1.9M	Hold	724,205	–	–	1.61%	10
2018 Q1	$2M	Hold	724,205	–	–	2.05%	7
2017 Q4	$2.33M	Hold	724,205	–	–	2.06%	7
2017 Q3	$3M	Hold	724,205	–	–	2.56%	5
2017 Q2	$3.85M	Hold	724,205	–	–	5.11%	4
2017 Q1	$4.16M	Hold	724,205	–	–	6.27%	4
2016 Q4	$2.87M	Buy	+724,205	New	+$2.58M	5.03%	4

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Knoll Capital Management's AVXL Position: Q2 2022 in Review

Knoll Capital Management sold out of Anavex Life Sciences (AVXL) in Q2 2022, closing a stake of 210,789 shares — an estimated $2.6M sold.

Knoll Capital Management first reported a position in AVXL in Q4 2016 and held it in 18 quarters. The position peaked at $4.16M in Q1 2017. 150 funds tracked by Wall St. Rank hold AVXL as of Q2 2022.

Knoll Capital Management reported no remaining Anavex Life Sciences position as of Q2 2022 after selling out during the quarter.
Knoll Capital Management sold 210,789 Anavex Life Sciences shares in Q2 2022, an estimated $2.6M.
Knoll Capital Management first reported a position in Anavex Life Sciences in Q4 2016 and held it in 18 quarters.
Knoll Capital Management's Anavex Life Sciences position peaked at $4.16M in Q1 2017.
150 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2022.

Based on Knoll Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.